[[{“value”:”
Karachi, Pakistan: Cannabis use is associated with clinical remission in Crohn’s disease (CD) patients and it represents a promising therapeutic option for managing the disease, according to a meta-analysis of placebo-controlled studies published in the Irish Journal of Medical Science.
A team of Pakistani investigators reviewed data from five randomized clinical trials involving 176 participants. In three of the trials, subjects used either cannabis cigarettes or a placebo. In two of the trials, subjects ingested either plant-derived extracts or a placebo.
Researchers determined: “The analysis indicates that cannabis may be beneficial in inducing clinical remission. … Specifically, individuals receiving cannabis treatment exhibited substantially higher rates of clinical remission at eight weeks compared to those in the control group.”
The study’s authors concluded: “In conclusion, the meta-analysis suggests that cannabis could be a promising therapeutic option for managing CD with minimal side effects. The findings … support its potential as an adjunct or alternative therapy, especially for patients unresponsive to conventional treatments.”
Full text of the study, “Cannabis use in Crohn’s disease: A systematic review and meta-analysis of randomized controlled trials,” appears in the Irish Journal of Medical Science. Additional information on cannabis and Crohn’s disease is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.
“}]] 5 randomized clinical trials involving 176 participants Read More
